Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Pyridostigmine is predominantly excreted unchanged via the kidneys, with up to 74% of renal clearance attributed to active tubular secretion. There is potential for competition with emtricitabine and tenofovir for active renal transport mechanisms, which may lead to increased concentrations of emtricitabine, tenofovir or pyridostigmine. Monitoring of renal function is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking